Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Company Deals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

Fineline Cube Dec 18, 2025
Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025
Company Deals

HBM BMS Multi-Specific Antibody Deal Targets $1 Billion Milestones

Fineline Cube Dec 18, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor

Fineline Cube Dec 20, 2025
Company Drug

Bio‑Thera NDA for VEGF‑A165 Antibody Targets $2B Wet AMD Market in China

Fineline Cube Dec 20, 2025
Policy / Regulatory

CDE Releases 71st Batch of Generic Reference Preparations with Updates and New Injecables

Fineline Cube Jun 12, 2023

The Center for Drug Evaluation (CDE) has released the 71st batch of chemical generic reference...

Company Deals

Hainan Boao Lecheng Partners with Recordati on Rare Disease Drug Development

Fineline Cube Jun 12, 2023

The Hainan Boao Lecheng International Medical Tourism Pilot Zone has announced a strategic partnership with...

Company Medical Device

NMPA Approves Shanghai Magic Medicine’s Innovative Multimodal Tumor Treatment System

Fineline Cube Jun 12, 2023

The National Medical Products Administration (NMPA) has granted marketing approval to Shanghai Magic Medicine’s multimodal...

Company Drug

Keymed Biosciences’ CM313 Monoclonal Antibody Shows Promise in Phase I Study for Multiple Myeloma

Fineline Cube Jun 12, 2023

China-based Keymed Biosciences Inc., (HKG: 2162) has announced that the latest results from a Phase...

Company Deals

Eccogene Secures $25 Million in Series B Financing to Advance Metabolic Disease Therapies

Fineline Cube Jun 12, 2023

Sino-US firm Eccogene Inc. has announced the closure of a Series B financing round, raising...

Company Drug

HutchMed Presents Updated Data on Hematological Malignancy Therapies at EHA and ICML

Fineline Cube Jun 12, 2023

HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) has announced that new and updated clinical data...

Company Drug

Reistone Biopharma’s Ivarmacitinib Accepted for Review by China’s CDE for Atopic Dermatitis

Fineline Cube Jun 9, 2023

Reistone Biopharma Co., Ltd, a company incubated by Hengrui Pharmaceuticals (SHA: 600276) with an investment...

Company Drug

CDE Indicates Priority Review for Overland ADCT’s Zynlonta and BeiGene’s Brukinsa

Fineline Cube Jun 9, 2023

The Center for Drug Evaluation (CDE) in China has indicated that Overland ADCT BioPharma (CY)...

Company Deals

Kexing Pharmaceutical Secures Commercial Rights for Convalife’s Neratinib Generic Outside China

Fineline Cube Jun 9, 2023

China-based Kexing Pharmaceutical (SHA: 688136) has announced a licensing agreement with compatriot firm Convalife, securing...

Company Deals

Lee’s Pharmaceutical Secures Rights to Eyedetec’s Dry Eye Device in Asia-Pacific

Fineline Cube Jun 9, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622)...

Company Drug

NMPA Approves Betta Pharmaceuticals’ Vorolanib for Second-Line RCC Treatment in Combination with Everolimus

Fineline Cube Jun 9, 2023

The National Medical Products Administration (NMPA) has granted approval for Betta Pharmaceuticals Co., Ltd’s (SHE:...

Company Drug

Zelgen Biopharmaceuticals’ ZGGS15 Earns FDA Approval for Advanced Solid Tumor Clinical Trial

Fineline Cube Jun 9, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...

Company Drug

CSPC Pharmaceutical’s CPO301 Receives Health Canada Approval for Phase I Study

Fineline Cube Jun 9, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received the green...

Company Deals R&D

Shanghai Fosun High Technology Partners with NICE for Joint Innovation Centers

Fineline Cube Jun 9, 2023

China-based conglomerate Shanghai Fosun High Technology (Group) Co., Ltd has entered into a partnership with...

Company Deals

Samyang Holdings Partners with Yxintent for Lafullen Dermal Filler in China

Fineline Cube Jun 9, 2023

South Korea-based Samyang Holdings Biopharm Group has secured a partnership with Hangzhou-based Yxintent, a specialist...

Deals

Sequoia Capital to Split into Three Units, Including Independent China and India/SEA Divisions

Fineline Cube Jun 8, 2023

US-based investment fund Sequoia Capital has declared plans to reorganize its business into three distinct...

Company Drug

Jacobio Pharma Gets Green Light for Phase I/IIa Study of PARP7 Inhibitor JAB-26766

Fineline Cube Jun 8, 2023

China-based Jacobio Pharma (HKG: 1167) has announced receiving approval in China to initiate a Phase...

Company

BioMarin Pharmaceutical to Discontinue Vimizim Import License in China

Fineline Cube Jun 8, 2023

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has announced its decision not to renew the Import Drug...

Company Drug

Vcanbio Receives NMPA Approval for VUM02 Stem Cell Therapy in Liver Failure and ARDS

Fineline Cube Jun 8, 2023

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced receiving clinical trial...

Company Drug

Dizal Pharmaceutical Presents Updates on Sunvozertinib and Golidocitinib at ASCO 2023

Fineline Cube Jun 8, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented updates on the clinical development of its...

Posts pagination

1 … 450 451 452 … 600

Recent updates

  • BeOne Medicines Names Dual Presidents in Leadership Overhaul
  • Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline
  • TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor
  • Bio‑Thera NDA for VEGF‑A165 Antibody Targets $2B Wet AMD Market in China
  • Novo Nordisk Submits CagriSema NDA for 20% Weight Loss in Obesity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

BeOne Medicines Names Dual Presidents in Leadership Overhaul

Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Company Drug

TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor

Company Drug

Bio‑Thera NDA for VEGF‑A165 Antibody Targets $2B Wet AMD Market in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.